Introduction
The sequence-specific transcription factor, p53, is a stressinduced regulator of cell function that has differing activities depending on p53 protein level, the inducing agent, and the cell type. p53 is also involved in lifespan regulation (Tyner et al., 2002; Maier et al., 2004) , cell cycle control (Levine, 1997), DNA repair, and apoptosis (Vogelstein et al., 2000; Gomez-Lazaro et al., 2004) . Because p53 is involved in cell death, it has the potential for playing a key role in the progression of degenerative diseases, and its role has been studied in some known disorders. In the neurodegenerative disorder spinal muscular atrophy (SMA), the normal interaction between SMN protein and p53 is reduced in the presence of SMN1 gene mutations, and this results in enhanced disease severity (Young et al., 2002) . Deletion of p53 in a mouse model of the polyglutamine repeat disorder spinocerebellar ataxia 1 (SCA1) has been found to rescue Purkinje cell pathology and slow disease progression (Shahbazian et al., 2001) . Most recently, p53 has been found to affect the phenotype of experimental models of the neurodegenerative disorder, Huntington's disease (HD) (Bae et al., 2005) . The connection between p53 and HD is particularly striking in light of the fact that mice nullizygous for p53 display variable expressivity of brain lesions very similar to those identified in Hdhnullizygous mouse brain. Neurodegeneration of the basal ganglia comparable to that seen in Hdh . HD is a progressive, autosomal dominant neurological disease that results from expansion of a polyglutamine (CAG) stretch located within the huntingtin protein (htt) encoded by the HD gene. Although htt exhibits widespread distribution in both the brain and peripheral tissues, the GABAergic medium spiny neurons of the striatum and the large pyramidal neurons in layers III, V, and VI of the cerebral cortex undergo preferential degeneration (Sharp et al., 1995; Ho et al., 2001; Sieradzan and Mann, 2001 ). The abundance of huntingtin protein does not appear to confer vulnerability on striatal neurons; rather, the expression of mutant htt in corticostriatal neurons seems to render them destructive to the striatal neurons that they innervate (Fusco et al., 1999) . Both prior and subsequent to neuronal death, the indirect pathway of basal ganglia output is affected most severely, resulting in an increase in involuntary movements associated with loss of proenkephalin expression. On a molecular level, intraneuronal inclusions that contain an aminoterminal fragment of mutant htt have been identified in the brains of both human HD patients and HD animal models (DiFiglia et al., 1997; Ho et al., 2001) . Inclusion formation does not directly correlate with increased neuronal vulnerability, as striatal neurons have been shown to form fewer inclusions than cortical neurons (Meade et al., 2002) . However, within the striatum, vulnerable neuronal subtypes do form more inclusions than unaffected neuronal subtypes, and they do so at an earlier age (Meade et al., 2002) . The consequences of inclusion formation have been unclear, with earlier reports suggesting a pathological function of inclusions in HD progression (Hackam et al., 1999) . However, other groups have found that aggregate inhibition is detrimental to the cell (Saudou et al., 1998) and that formation of aggregates can actually predict improved survival and lead to decreased levels of mutant htt 
